This week, members of the U.S. Food and Drug Administration (FDA) will convene to discuss Pfizer’s COVID-19 vaccine, bringing the inoculation closer to receiving authorization to be distributed throughout the country. A couple hotly anticipated initial public offerings will also draw investor focus.
Pfizer’s vaccine review
Equity markets for weeks have been propped up amid a flurry of upbeat vaccine-related news, as drugmakers unveiled efficacy data that far exceeded health officials’…
Source link
